Dr. Eddy Pasquier completed his PhD in Oncology at the University of Aix-Marseille, France in 2006. Shortly after, he joined the Children’s Cancer Institute Australia (CCIA), first as a Post-Doctoral Research Officer and then as a Cancer Institute New South Wales Research Fellow. Currently, he is a Senior Research Officer and leads a small research team within the Tumour Biology and Targeting Program of CCIA. He is also a Lecturer (Conjoint) in the School for Women’s and Children’s Health at the Faculty of Medicine, University of New South Wales (Sydney, Australia). His awards include the Young Tall Poppy Science Award 2011 from the Australian Institute of Policy & Science, the Dean’s Rising Star Award 2010 from the Faculty of Medicine, University of New South Wales, and the Children’s Cancer Institute Australia Award 2008 for outstanding achievements in research and community engagement.
Over the past 10 years, Dr Pasquier has made significant contributions to the fields of tumour angiogenesis and innovative cancer therapies. His work on metronomic chemotherapy in particular contributed to elucidate some of the underlying molecular and cellular mechanisms of action of this multi-faceted therapy. Through his long-standing collaboration with Metronomics Global Health Initiative co-founder, Dr Nicolas Andre, Dr Pasquier also helped in the development of more effective metronomic protocols to be used in childhood cancer patients living in both high-income and low- to middle-income countries.
Drs Andre and Pasquier share the same vision that a different approach to cancer treatment is not only possible but mandatory. Their research effort is based on this common philosophy and aims at developing constraint-adapted, effective, cheap and non-toxic cancer therapies that can be used to treat childhood cancer patients wherever they live.
Selected publications about metronomics:
- André N, Abed S, Orbach D, Armari Alla C, Padovani L, Pasquier E et al. Pilot study of a pediatric metronomic 4-drug regimen.Oncotarget. 2012
- Pasquier E et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget 2011
- Pasquier E et al. Moving forward with metronomic treatments: meeting report of the 2nd international workshop on metronomic and anti-angiogenic chemotherapy in paediatric oncology. Translational Oncology 2011
- Fousseyni T, Diawara M, Pasquier E, André N. Children treated with metronomic chemotherapy in a low-income country: Metro-Mali-01. Journal of Pediatric Hematology Oncology 2011
- André N, Pasquier E, Gentet JC, Kamen B. Looking at the seemingly paradoxical effect of vinblastine in anaplastic large cell lymphoma from a “metronomic” point of view. Journal of Clinical Oncology 2011
-Pasquier E, Kavallaris M, André N. Metronomic Chemotherapy : New rationale for new directions. Nature Reviews Clinical Oncology 2010
- André N, Pasquier E. For cancer seek and destroy better than live and let live? Nature 2009
- André N, Pasquier E. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nature Reviews Clinical Oncology 2008
Other significant publications:
- Kan CY, Wen VW, Pasquier E et al. Endothelial cell dysfunction and cytoskeletal changes associated with repression of p16INK4a during immortalization. Oncogene 2012
- Shum MSY, Pasquier E et al. γ-actin regulates cell migration and modulates the ROCK signaling pathway. FASEB Journal 2011
- Pasquier E et al. ENMD-1198, a new analog of 2-methoxyestradiol, displays both anti-angiogenic and vascular-disrupting properties. Molecular Cancer Therapeutics 2010
- Pasquier E, Dias S. Endothelial progenitor cells: hope beyond controversy? Current Cancer Drug Targets 2010
- Pasquier E et al. Microtubule-targeting agents in angiogenesis: where do we stand? Drug Resistance Updates 2006
Pasquier E et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Research 2005 Pasquier E et al. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signalling pathway. Molecular Cancer Therapeutics 2004